Randomized Pilot Trial of Omega-3 Fatty Acids or Placebo in Peri- or Post-Menopausal Women at High Risk for Breast Cancer Undergoing a Weight Loss Intervention
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 46
- Locations
- 1
- Primary Endpoint
- Dropout rate
Study Overview
Brief Summary
The purpose of this study is to determine if high dose supplementation with the omega-3 fatty acids EPA and DHA, when added to a weight loss program, is well tolerated in the study population and if there is an increase in the favorable change in blood and tissue breast cancer risk factors when compared to weight loss alone.
Detailed Description
Subjects will all participate in a 6-month weight loss intervention. Subjects will be randomized to receive either blinded placebo or omega-3 fatty acids for 6 months.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 45 Years to 70 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Evidence of Hyperplasia with Masood score of 13 or higher and 500 or more epithelial cells on cytology slide of screening Random Periareolar Fine Needle Aspiration (RPFNA)
- •Access to smart phone and or computer
- •Willing to comply with diet, exercise and lifestyle modification during weight reduction and maintenance phase.
- •Willing to start the dietary and exercise intervention within 9 months of RPFNA
- •Willing to complete quality of life questionnaires at multiple visits
- •Willing to have a medical history and physical at multiple visits
- •Willing to have an additional RPFNA at two additional visits
- •Be willing to have blood drawn at multiple visits
- •Willing to sign and able to understand consent for the RPFNA's and study participation
- •Reasonable hematopoetic, kidney and liver function consistent with safe participation on this trial.
Exclusion Criteria
- •Having taken medications that seriously affect metabolism such as steroids, dexatrim or other diet drugs within 3 weeks of study registration
- •Have changed dose or type of hormone supplementation within 3 months
- •Currently receiving other investigational agents
- •Have been on a chemoprevention trial within 6 months or taken a Selective Estrogen Receptor Modulator or aromatase inhibitor within last 6 months.
- •Need for chronic use of aspirin, nonsteroidal anti-inflamatory drug (NSAID) or other anti-inflammatory agents
- •Taking metformin, or other diabetes medications
- •Taking statins
- •Unable to participate in moderate intensity exercise (walking, treadmill, elliptical, water aerobics)
- •Would be unable to participate, by phone, in weekly phone call sessions
- •Cells suspicious for malignancy as assessed by cytotechnologist or cytopathologist.
Arms & Interventions
Weight Loss + Placebo
Participants will be instructed to exercise and follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of placebo a day beginning 2 weeks after starting their diet and exercise routine. Placebo capsule will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.
Intervention: Diet and Exercise (Other)
Weight Loss + Omega-3 FA
Participants will be instructed to follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of Omega-3 FA (fatty acids) a day beginning 2 weeks after starting their diet and exercise routine. Omega-3 FA will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.Each Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
Intervention: Omega-3 Fatty Acids (Dietary Supplement)
Weight Loss + Omega-3 FA
Participants will be instructed to follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of Omega-3 FA (fatty acids) a day beginning 2 weeks after starting their diet and exercise routine. Omega-3 FA will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.Each Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
Intervention: Diet and Exercise (Other)
Weight Loss + Placebo
Participants will be instructed to exercise and follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of placebo a day beginning 2 weeks after starting their diet and exercise routine. Placebo capsule will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.
Intervention: Placebo Capsule (Other)
Outcomes
Primary Outcomes
Dropout rate
Time Frame: Up to 6 Months
Measured as the number of participants that dropout before diet+intervention period is complete
Secondary Outcomes
- Modulation of breast cancer risk biomarkers(Change from Baseline to 12 Months)
- Modulation of breast cancer risk biomarkers in benign breast tissue(Change from Baseline to 12 Months)
- Weight gain(Change from 6 Months to 12 Months)
- Study design feasibility(Up to 6 months)
- Change in Gut Microbiome(Change from Baseline to Month 6)
- Modulation of breast cancer risk biomarkers(Change from Baseline to 6 Months)
- Modulation of breast cancer risk biomarkers in benign breast tissue(Change from Baseline to 6 Months)
Investigators
Carol Fabian, MD
Professor, Director Breast Cancer Prevention Unit
University of Kansas Medical Center